Key Takeaways
- • Tim Holmes serves as Managing Member of Genesis Research and Asset Management, an investment firm focused on the life sciences sector with a track record of institutional asset allocation since 2008.
- • Holmes brings over 30 years of experience in the bioscience sector, including prior roles in clinical research, EU pharmaceutical pricing, and clinical supply chain management at firms including Telios Pharma.
- • Genesis Research and Asset Management's investment philosophy centers on "winning by not losing"—a risk management approach relevant to institutional capital deployment in life sciences investing.
- • Holmes operates as a fractional strategic advisor and coach to leaders and organizations managing money, people, and systems under conditions of uncertainty, reflecting a consulting engagement model alongside his primary role.
Summary
Tim Holmes is the Managing Member of Genesis Research and Asset Management, an investment firm specializing in the life sciences sector. According to World Finance, Holmes was interviewed on the firm's investment approach, which emphasizes "winning by not losing"—a foundational principle that underscores a defensive, risk-conscious strategy for capital allocation.
Holmes brings substantial domain expertise to the role, with more than 30 years of experience across the bioscience sector. His career has spanned clinical research, European pharmaceutical pricing, and clinical supply chain management, including a previous position as Senior Manager of Clinical Supply Chain at Telios Pharma. This combination of operational and strategic experience positions him to evaluate life sciences investments from both technical and commercial perspectives.
Beyond his primary role at Genesis Research and Asset Management, Holmes operates as a fractional strategic advisor and executive coach, providing guidance to leaders and organizations managing capital, people, and complex systems amid uncertainty. This dual engagement suggests a consulting-oriented approach to stakeholder relationships within the institutional investment community.
The firm has been actively deploying capital since 2008, accumulating institutional asset allocations over a 12+ year period. The "winning by not losing" philosophy reflects a risk management ethos that resonates with institutional investors and family offices seeking downside protection alongside return generation in the specialized life sciences investment space.
Holmes brings substantial domain expertise to the role, with more than 30 years of experience across the bioscience sector. His career has spanned clinical research, European pharmaceutical pricing, and clinical supply chain management, including a previous position as Senior Manager of Clinical Supply Chain at Telios Pharma. This combination of operational and strategic experience positions him to evaluate life sciences investments from both technical and commercial perspectives.
Beyond his primary role at Genesis Research and Asset Management, Holmes operates as a fractional strategic advisor and executive coach, providing guidance to leaders and organizations managing capital, people, and complex systems amid uncertainty. This dual engagement suggests a consulting-oriented approach to stakeholder relationships within the institutional investment community.
The firm has been actively deploying capital since 2008, accumulating institutional asset allocations over a 12+ year period. The "winning by not losing" philosophy reflects a risk management ethos that resonates with institutional investors and family offices seeking downside protection alongside return generation in the specialized life sciences investment space.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.